EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections

Amer El Ghali iD, Ashlan J Kunz Coyne iD, Kristen Lucas, Molly Tieman, Xhilda Xhemali, Suet-Ping Lau, Gabriela Iturralde, Andrew Purdy, Dana J Holger, Esther Garcia, Michael P Veve, Michael J Rybak iD

Microbiology Spectrum · 06.02.2024 · 12 (2)

DOI: 10.1128/spectrum.03108-23 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Microbiology Spectrum, erschienen am 06.02.2024. Verfasst von Amer El Ghali und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Cefiderocol, Anti-Bacterial Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multi-drug resistant gram-negative bacteria present a significant global health threat. Cefiderocol (CFDC), a siderophore cephalosporin, has shown potential in combating this threat, but with the currently available data, its role in therapy remains poorly defined. This multi-center, retrospective cohort study evaluated the real-world application of CFDC across six U.S. medical centers from January 2018 to May 2023. Patients aged ≥18 years and who had received ≥72 hours of CFDC were included. The primary outcome was a composite of clinical success: survival at 30 days, absence of symptomatic microbiologic recurrence at 30 days following CFDC treatment initiation, and resolution of signs and symptoms. Secondary outcomes included time to CFDC therapy and on-treatment non-susceptibility to CFDC. A total of 112 patients were included, with median (interquartile range [IQR]) APACHE II scores of 15 (19–18). Clinical success was observed in 68.8% of patients, with a mortality rate of 16.1% and comparable success rates across patients infected with carbapenem-resistant gram-negative infections. The most common isolated organisms were Pseudomonas aeruginosa (61/112, 54.5%, of which 55/61 were carbapenem-resistant) and carbapenem-resistant Acinetobacter baumannii (32/112, 28.6%). Median (IQR) time to CFDC therapy was 77 (14–141) hours. Two patients experienced a non-anaphylactic rash as an adverse drug reaction. On-treatment non-susceptibility to CFDC was found in six patients, notably due to P. aeruginosa and A. baumannii . IMPORTANCE CFDC was safe and clinically effective as a monotherapy or in combination in treating a variety of carbapenem-resistant gram-negative infections. Further prospective studies are warranted to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefiderocolAnti-Bacterial AgentsHumansAdolescentAdultRetrospective StudiesCephalosporinsCarbapenemsGram-Negative BacteriaMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Acinetobacter baumanniiCefiderocolPseudomonas aeruginosacarbapenem-resistantgram-negative resistance

Substanzen

CefiderocolAnti-Bacterial AgentsCephalosporinsCarbapenems

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
  • Department of Pharmacy, Indiana University Health, Bloomington, Indiana, USA.
  • Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pharmacy, Orlando Health, Orlando, Florida, USA.
  • Department of Pharmacy, Memorial Hospital West, Pembroke Pines, Florida, USA.
  • Department of Pharmacy Practice, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.

ORCID-Profile: Amer El Ghali, Ashlan J Kunz Coyne, Michael J Rybak

Zitieren

APA

El Ghali, A., Kunz Coyne, A. J., Lucas, K., Tieman, M., Xhemali, X., Lau, S., Iturralde, G., Purdy, A., Holger, D. J., Garcia, E., Veve, M. P., & Rybak, M. J. (2024). Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiology Spectrum, 12(2). https://doi.org/10.1128/spectrum.03108-23

Vancouver

El Ghali A, Kunz Coyne AJ, Lucas K, Tieman M, Xhemali X, Lau S, et al. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiology Spectrum. 2024;12(2). doi:10.1128/spectrum.03108-23

BibTeX
@article{ElGhali2024,
  author = {El Ghali, Amer and Kunz Coyne, Ashlan J and Lucas, Kristen and Tieman, Molly and Xhemali, Xhilda and Lau, Suet-Ping and Iturralde, Gabriela and Purdy, Andrew and Holger, Dana J and Garcia, Esther and Veve, Michael P and Rybak, Michael J},
  title = {Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {2},
  doi = {10.1128/spectrum.03108-23}
}
Kostenlos starten →